培美曲塞对比多西他赛单药治疗晚期非小细胞肺癌的临床效果分析

目的:分析培美曲塞对比多西他赛单药治疗晚期非小细胞肺癌的临床效果。方法:撷取本院收治的90例晚期非小细胞肺癌患者,撷取时间是自2015年8月至2017年8月,分观察组(n=45)和对照组(n=45)。对照组予以多西他赛治疗,观察组予以培美曲塞。比较不良反应。结果:与对照组不良反应发生率比较,观察组较低,差异突出,P<0.05。结论:培美曲塞治疗晚期非小细胞肺癌患者的病情,出现的不良反应更少,安全性更高,值得借鉴。

Objective:To analyze the clinical effect of pemetrexed versus docetaxel in the treatment of advanced non-small cell lung cancer.Methods:Ninety patients with advanced non-small cell lung cancer admitted to our hospital were recruited from August 2015 to August 2017.The observation group(n=45)and the control group(n=45).The control group was treated with docetaxel,and the observation group received pemetrexed.Adverse reactions.Results:Compared with the incidence of adverse reactions in the control group,the observation group was lower and the difference was prominent(P<0.05).Conclusion:Pemetrexed treatment of advanced non-small cell lung cancer patients with fewer adverse reactions,higher safety,it is worth learning.